DHSC Perspectives on WHA 75.8 implementation

Dr Mary De Silva, Deputy Chief Scientific Adviser, UK Department of Health and Social Care
The resolution outlines a package of actions for Member States, non-State actors and the WHO to enable well-designed and implemented trials globally.

All actors have distinct and complementary roles to play in implementation. The WHO’s guidance will provide a helpful roadmap.

1. Enhance clinical trial capability
2. Strengthen international collaboration & coordination
3. Improve standards
4. Streamline regulatory and ethical processes

Outcome:
More efficient and diverse global clinical trials ecosystem, producing effective health interventions for diverse populations in public health emergencies and for ongoing global health challenges.
New WHO guidance marks a great opportunity to make existing initiatives more than the sum of their parts

<table>
<thead>
<tr>
<th>Theme</th>
<th>Relevant Initiative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enhance clinical trial capability</td>
<td>CIOMS report on clinical research in resource-limited settings, TDR activity to map existing clinical trial networks and infrastructures.</td>
</tr>
</tbody>
</table>
| Strengthen international collaboration and coordination | **Coordinating funding**: the Global Research Collaboration for Infectious Diseases (GloPID-R); regional initiatives such as the European and Developing Countries Clinical Trial Partnership (EDCTP).

  **Promoting collaboration**: bespoke international networks operating on regional footprints, such as ECRAID, ECRIN in Europe. |
| Improving Standards                        | ICH E6 Good Clinical Practice; Wellcome Trust’s **Good Clinical Trials Collaborative** guidance.                                                      |
| Streamline regulatory and ethical processes | International Coalition of Medicines Regulatory Authorities (**ICMRA**), regional networks such as AVAREF.                                             |

Much is underway, however this is **no clear understanding of the current gaps at an ecosystem level**, across and within different global regions, or the evidence-based roles of different actors in ecosystem strengthening.

WHO has a role to play in helping us understand current capacity and the roles of actors in strengthening.
GloPID-R are working to support implementation of WHA75.8

- **33 Member and 7 Observer Organisations**, consisting of public and philanthropic clinical research funders.

- GloPID-R have launched a **new report with recommendations to support coordinated approaches to clinical trial funding**, aligned with WHA75.8 themes.

- **This forum provides a vehicle to support Member State implementation** of coordinated approaches to clinical trial funding.
Work is required in many areas, particularly understanding the infrastructure required to pivot during a pandemic

1) **Understanding and developing the required pre-existing infrastructure globally** to enable effective and coordinated clinical trial responses to pandemic threats, such as clinical trial networks and standing trial platforms.

2) **Understanding the mechanisms required to pivot routine clinical trial capacity** across the global ecosystem to trigger effective pandemic response.

3) **Understanding the roles of all actors in coordination** and facilitating high quality research more readily through trials.
To support this, the UK is chairing a new international Ministry of Health forum to understand MoH roles as part of the solution

- 8 member countries across global regions. Membership is open to all Member States wishing to engage.

- Focused on developing policy solutions to deliver the actions requested of WHO Member States in the resolution.

- WHO observer membership to promote alignment with the guidance development and WHO public consultation findings.

- Particular focus on how Ministries of Health can best support strong trial networks and multi-country trials.

**Diagram:**

1. **Discovery**
   - Learning from COVID-19 innovations
   - Understanding barriers and facilitators to best practice

2. **National Policy Enablers**
   - Exploring specific themes, such as coordinated funding models

3. **International coordination**
   - Understanding how to connect domestic best practice internationally

4. **Options for implementation**
   - Delivery in practice
The UK remains committed to strengthening clinical trials in collaboration with international partners

• We encourage Member States to join existing initiatives to strengthen clinical trials (such as GloPID-R, ICMRA) and engage through other existing multilateral partnerships and organisations.

• We are happy to discuss membership to the clinical trials Group of Friends with interested Member States.

• We look forward to continued engagement with WHO, Member States and non-State actors to turn WHA75.8 from vision to reality.